# **Product Datasheet**

# Complement C4d Antibody (SPM545) [FITC] NBP2-34421F

Unit Size: 0.1 ml

Store at 4C in the dark.

www.novusbio.com



technical@novusbio.com

Protocols, Publications, Related Products, Reviews, Research Tools and Images at: www.novusbio.com/NBP2-34421F

Updated 10/26/2023 v.20.1

Earn rewards for product reviews and publications.

Submit a publication at www.novusbio.com/publications
Submit a review at www.novusbio.com/reviews/destination/NBP2-34421F



#### NBP2-34421F

Complement C4d Antibody (SPM545) [FITC]

Complement C4d Antibody (SPM545) [FITC]	
Product Information	
Unit Size	0.1 ml
Concentration	Please see the vial label for concentration. If unlisted please contact technical services.
Storage	Store at 4C in the dark.
Clonality	Monoclonal
Clone	SPM545
Preservative	0.05% Sodium Azide
Isotype	IgG1 Kappa
Conjugate	FITC
Purity	Protein A or G purified
Buffer	PBS
Product Description	
Host	Mouse
Gene ID	720
Gene Symbol	C4A
Species	Human
Marker	Acute Humoral Rejection Marker
Specificity/Sensitivity	This monoclonal antibody is specific to Complement 4d (C4d) and it reacts with the secreted as well as cell-bound C4d.C4d is a degradation product of the activated complement factor C4b. Complement 4b is typically activated by binding of Abs to specific target molecules. Following activation and degradation of the C4 molecule, thio-ester groups are exposed, which allow transient, covalent binding of the degradation product Complement 4d to endothelial cell surfaces and extracellular matrix components of vascular basement membranes near the sites of C4 activation. The presence of C4d in peritubular capillaries is a key indicator for acute humoral (i.e. antibody-mediated) rejection of kidney, heart, pancreas and lung allografts. As an established marker of antibody-mediated acute renal allograft rejection and its proclivity for endothelium, this component can be detected in peritubular capillaries in chronic renal allograft rejection as well as hyperacute rejection, acute vascular rejection, acute cellular rejection, and borderline rejection. It has been shown to be a significant predictor of transplant kidney graft survival. Anti-C4d, combined with anti-C3d, can be utilized as a tool for diagnosis of allograft rejection that may warrant a prompt and aggressive anti-rejection treatment.
Immunogen	Recombinant human Complement Complement C4d protein
Product Application Details	
Applications	Immunocytochemistry/Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Paraffin
Recommended Dilutions	Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin
Application Notes	Optimal dilution of this antibody should be experimentally determined.





## Novus Biologicals USA

10730 E. Briarwood Avenue Centennial, CO 80112

USA

Phone: 303.730.1950 Toll Free: 1.888.506.6887

Fax: 303.730.1966 novus@novusbio.com

#### **Bio-Techne Ltd**

19 Barton Lane Abingdon Science Park Abingdon, OX14 3NB, United Kingdom Phone: (44) (0) 1235 529449

Free Phone: 0800 37 34 15 Fax: (44) (0) 1235 533420 info.EMEA@bio-techne.com

#### **Bio-Techne Canada**

21 Canmotor Ave Toronto, ON M8Z 4E6

Canada

Phone: 905.827.6400 Toll Free: 855.668.8722 Fax: 905.827.6402

canada.inquires@bio-techne.com

#### **General Contact Information**

www.novusbio.com

Technical Support: technical@novusbio.com

Orders: orders@novusbio.com General: novus@novusbio.com

### **Products Related to NBP2-34421F**

NBP1-43319F Mouse IgG1 Kappa Isotype Control (P3.6.2.8.1) [FITC]

210-TA-005 TNF-alpha [Unconjugated]
DIP100 CXCL10/IP-10/CRG-2 [HRP]
DY1707 C-Reactive Protein/CRP [Biotin]

#### Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP2-34421F

Earn gift cards/discounts by submitting a publication using this product: www.novusbio.com/publications

